Scientist has get success in finding out the potential of a protein that can be targeted to stop tumour growth. The new success will certainly be open the new horizon in the treatment of caner as it can be beneficial in stopping the tumour growth.
Researchers from the University of East Anglia in Britain have found that researchers should not give up on the beta3-integrin protein, which has been a major target in cancer drug design for the last two decades.
Stephen Robinson of the School of Biological Sciences, University of East Anglia said, "These findings have re-established the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be re-focused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist.”
According to the research, "Circulation Research", also explained why the most advanced version of avß3-integrin - a stem cell marker and driver of tumour cell resistance - failed clinical trials to treat aggressive forms of brain cancer.
"This research helps to explain why these very promising drugs aren't meeting with the success that was anticipated and it suggests a way forward - how to make them work better,” Robinson said.
We have shown how tumours continue to grow despite treatment which should block blood vessel recruitment. They modulate how they are recruiting their blood vessels by using a different pathway from the one that is being targeted,” he said.
He further added that this research also shows that timing is critical when targeting the protein beta3-integrin.
(With inputs from IANS)
|
|
Comments:
